AOTMiT: Transparency Council, incl. o a drug for esophageal cancer and ALL

The agenda includes:
Preparation of a position on the evaluation of Keytruda (pembrolizumabum) under the drug program: "Treatment of esophageal cancer (ICD-10: C15)".
Preparation of a position on the validity of granting consent for the reimbursement of the medicinal product Gammalon (gamma-aminobutyric acid) in the indications: autism; motor aphasia; Sensory and sensorimotor aphasia as well as delayed psychomotor development (mainly speech and cognitive functions).
Preparation of an opinion on the reimbursement of drugs containing the active substance posaconazolum in the indications: high-risk acute lymphoblastic leukemia in children under 18 years of age; recurrence of acute lymphoblastic leukemia in children under 18 years of age; recurrence of acute myeloid leukemia in children under 18 years of age

Source: AOTMiT